Oppenheimer Starts Regulus Therapeutics (RGLS) at Outperform
Tweet
Share
E-mailGet Alerts RGLS Hot Sheet
Price: $8.16 --0%
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
4 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Oppenheimer analyst Andreas Argyrudes initiates coverage on Regulus Therapeutics (NASDAQ: RGLS) with a Outperform rating.
For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.
Shares of Regulus Therapeutics closed at $1.80 yesterday.
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy
- H.C. Wainwright Assumes Alpha Compute Corp. (ALP) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
